Topical Ocular Biologics with Claris Bio's Clarke Atwell
Business Of Biotech
00:00
The Evolution of Ocular Treatment Paradigm
This chapter discusses the shift in administration paradigm for ocular indications, focusing on bringing biologics to the front of the eye for underserved indications like neurotrophic keratitis. It highlights the introduction of Oxervate as the first biologic approved for a topical front-of-the-eye condition, emphasizing its efficacy and potential benefits for patients beyond wound resolution. The chapter also addresses the challenges with traditional treatments, the importance of stable molecules in drug formulation, and the need to prove the effectiveness of topical ocular biologics while being prepared for unexpected challenges in clinical trials.
Transcript
Play full episode
